Fenofibrate
Fenofibrate. PPARα agonist → increased hepatic fatty-acid oxidation + lipoprotein-lipase transcription → ~50% TG reduction + modest HDL rise. LDL… Oral half-life 20 h.
PPARα agonist → increased hepatic fatty-acid oxidation + lipoprotein-lipase transcription → ~50% TG reduction + modest HDL rise. LDL effect modest. Reduces CV events in hypertriglyceridemic diabetic populations (FIELD, ACCORD-Lipid subgroups).
PK: EVERY STORED VALUE DESCRIBES FENOFIBRIC ACID AND THE RECORD CALLED IT FENOFIBRATE. Its own label says no unchanged fenofibrate is detected in plasma, and the cited mass-balance paper agrees from the other end - "The principal compound in feces was unchanged fenofibrate" - so the parent appears only unabsorbed. That citation is a 14C metabolite-identification study reporting NO half-life, NO volume, NO bioavailability and NO absorption rate, and all four values were class 1 against it. F 0.60 IS A URINARY RECOVERY PERCENTAGE, traceable inside the cited abstract itself - "59% in the urine" - and the quantity is unknowable in principle: "The absolute bioavailability of fenofibrate cannot be determined due to its being virtually insoluble in aqueous media suitable for injection; however ... approximately 60% of the dose appeared in urine". One sentence contains both the true fact and the numeral that was mistaken for it. F is pinned to 1 because the retained volume is apparent. ka 1.56 is a back-derivation implying a round 2.5 h peak, against a real "peak plasma levels attained in 6 to 8 hours". The analyte, the molecular weight and the occupancy EC50 are corrected together, because the stored EC50 converted a fenofibric-acid molar value using the PARENT mass.
Pharmacokinetics
- Oral — t½ 20 h · F 100% · Vd 63 L
Related compounds
- Statins — caution
Sources: PMID:16310551, PMID:15572716, PMID:14982965, PMID:40052566, PMID:12581543, PMID:1970770